- Home
- SPRO vs RCKY Comparison
SPRO vs RCKY Comparison
Compare SPRO & RCKY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RCKY
- Stock Information
- Founded
- SPRO 2013
- RCKY 1932
- Country
- SPRO United States
- RCKY United States
- Employees
- SPRO N/A
- RCKY N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RCKY Shoe Manufacturing
- Sector
- SPRO Health Care
- RCKY Consumer Discretionary
- Exchange
- SPRO Nasdaq
- RCKY Nasdaq
- Market Cap
- SPRO 162.1M
- RCKY 174.1M
- IPO Year
- SPRO 2017
- RCKY 1993
- Fundamental
- Price
- SPRO $2.20
- RCKY $22.98
- Analyst Decision
- SPRO Buy
- RCKY Hold
- Analyst Count
- SPRO 4
- RCKY 1
- Target Price
- SPRO $5.00
- RCKY $20.00
- AVG Volume (30 Days)
- SPRO 789.2K
- RCKY 49.7K
- Earning Date
- SPRO 08-04-2025
- RCKY 07-29-2025
- Dividend Yield
- SPRO N/A
- RCKY 2.64%
- EPS Growth
- SPRO N/A
- RCKY 2.41
- EPS
- SPRO N/A
- RCKY 1.84
- Revenue
- SPRO $44,584,000.00
- RCKY $454,939,000.00
- Revenue This Year
- SPRO N/A
- RCKY $6.67
- Revenue Next Year
- SPRO N/A
- RCKY $4.25
- P/E Ratio
- SPRO N/A
- RCKY $12.77
- Revenue Growth
- SPRO N/A
- RCKY N/A
- 52 Week Low
- SPRO $0.51
- RCKY $11.93
- 52 Week High
- SPRO $3.22
- RCKY $37.21
- Technical
- Relative Strength Index (RSI)
- SPRO 33.44
- RCKY 48.92
- Support Level
- SPRO $2.30
- RCKY $22.93
- Resistance Level
- SPRO $2.45
- RCKY $23.89
- Average True Range (ATR)
- SPRO 0.12
- RCKY 0.89
- MACD
- SPRO -0.07
- RCKY -0.12
- Stochastic Oscillator
- SPRO 2.80
- RCKY 24.71
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.